<DOC>
	<DOCNO>NCT00427895</DOCNO>
	<brief_summary>This study ass safety , tolerability immune response 13-valent pneumococcal conjugate vaccine ( 13vPnC ) compare 23-valent Pneumococcal Polysaccharide Vaccine ( 23vPS ) . Although study start 1 population , amendment original protocol reflect three participant population . Three age cohort enrol . The first cohort ( age 60-64 ) blind . Cohort 2 ( age 50-59 ) cohort 3 ( age 18-49 ) open label . Subjects cohorts 1 2 receive 2 vaccination 3-4 year apart . Subjects cohort 3 receive 1 vaccination . All participant na√Øve 23vPS . Comparisons immune response different cohort do .</brief_summary>
	<brief_title>Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine Adults</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>First Cohort : Healthy Male female adult 60 64 year age time enrollment . Second Cohort : Healthy Male female adult 50 59 year age time enrollment . Third Cohort : Healthy Male female adult 18 49 year age time enrollment . Previous immunization license experimental pneumococcal vaccine . Serious chronic disorder include metastatic malignancy , severe chronic obstructive pulmonary disease ( COPD ) require supplemental oxygen , end stage renal disease without dialysis , clinically unstable cardiac disease , disorder investigator 's opinion precludes subject participate study . Known suspect impairment immunological function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Pneumococcal Infections Prevention Control</keyword>
</DOC>